Clarity Pharmaceuticals: From $1 to $9 a share - Could this eventually be a cure for prostate cancer? 

Listen to ASX-listed Clarity Pharmaceuticals Executive Chair Alan Taylor talk to Matt Birney on the Bulls N’ Bears Report about Clarity’s amazing clinical trial results that saw a complete response in one patient and lots with a 90 per cent plus reduction in signs of prostate cancer using “copper” based radiopharmaceuticals.

Clarity Pharmaceuticals: From $1 to $9 a share - Could this eventually be a cure for prostate cancer? 
Listen to ASX-listed Clarity Pharmaceuticals Executive Chair Alan Taylor talk to Matt Birney on the Bulls N’ Bears Report about Clarity’s amazing clinical trial results that saw a complete response in one patient and lots with a 90 per cent plus reduction in signs of prostate cancer using “copper” based radiopharmaceuticals.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N’ Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia’s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N&rsquo; Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia&rsquo;s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Advertisement